|
1
|
Khanna KK and Jackson SP: DNA
double-strand breaks: Signaling, repair and the cancer connection.
Nat Genet. 27:247–254. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ciccia A and Elledge SJ: The DNA damage
response: Making it safe to play with knives. Mol Cell. 40:179–204.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chun J, Buechelmaier ES and Powell SN:
Rad51 paralog complexes BCDX2 and CX3 act at different stages in
the BRCA1-BRCA2-dependent homologous recombination pathway. Mol
Cell Biol. 33:387–395. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Badie S, Liao C, Thanasoula M, Barber P,
Hill MA and Tarsounas M: RAD51C facilitates checkpoint signaling by
promoting CHK2 phosphorylation. J Cell Biol. 185:587–600. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Liu Y, Masson JY, Shah R, O'Regan P and
West SC: RAD51C is required for Holliday junction processing in
mammalian cells. Science. 303:243–246. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kuznetsov S, Pellegrini M, Shuda K,
Fernandez-Capetillo O, Liu Y, Martin BK, Burkett S, Southon E, Pati
D, Tessarollo L, et al: RAD51C deficiency in mice results in early
prophase I arrest in males and sister chromatid separation at
metaphase II in females. J Cell Biol. 176:581–592. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Meindl A, Hellebrand H, Wiek C, Erven V,
Wappenschmidt B, Niederacher D, Freund M, Lichtner P, Hartmann L,
Schaal H, et al: Germline mutations in breast and ovarian cancer
pedigrees establish RAD51C as a human cancer susceptibilitygene.
Nat Genet. 42:410–414. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pelttari LM, Heikkinen T, Thompson D,
Kallioniemi A, Schleutker J, Holli K, Blomqvist C, Aittomäki K,
Bützow R and Nevanlinna H: RAD51C is a susceptibility gene for
ovarian cancer. Hum Mol Genet. 20:3278–3288. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Loveday C, Turnbull C, Ruark E, Xicola RM,
Ramsay E, Hughes D, Warren-Perry M and Snape K: Breast Cancer
Susceptibility Collaboration (UK), Eccles D, et al: Germline
RAD51C mutations confer susceptibility to ovarian cancer. Nat
Genet. 44:475–476. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Vaz F, Hanenberg H, Schuster B, Barker K,
Wiek C, Erven V, Neveling K, Endt D, Kesterton I, Autore F, et al:
Mutation of the RAD51C gene in a Fanconi anemia-like disorder. Nat
Genet. 42:406–409. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Forbes SA, Beare D, Gunasekaran P, Leung
K, Bindal N, Boutselakis H, Ding M, Bamford S, Cole C, Ward S, et
al: COSMIC: Exploring the world's knowledge of somatic mutations in
human cancer. Nucleic Acids Res. 3:D805–D811. 2015. View Article : Google Scholar
|
|
12
|
Jiang H, Pritchard JR, Williams RT,
Lauffenburger DA and Hemann MT: A mammalian functional-genetic
approach to characterizing cancer therapeutics. Nat Chem Biol.
7:92–100. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dickins RA, Hemann MT, Zilfou JT, Simpson
DR, Ibarra I, Hannon GJ and Lowe SW: Probing tumor phenotypes using
stable and regulated synthetic microRNA precursors. Nat Genet.
37:1289–1295. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jiang H, Reinhardt HC, Bartkova J,
Tommiska J, Blomqvist C, Nevanlinna H, Bartek J, Yaffe MB and
Hemann MT: The combined status of ATM and p53 link tumor
development with therapeutic response. Genes Dev. 23:1895–1909.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pfaffl MW: A new mathematical model for
relative quantification in real-time RT-PCR. Nucleic Acids Res.
29:e452001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cai MY, Tong ZT, Zheng F, Liao YJ, Wang Y,
Rao HL, Chen YC, Wu QL, Liu YH, Guan XY, et al: EZH2 protein: A
promising immunomarker for the detection of hepatocellular
carcinomas in liver needle biopsies. Gut. 60:967–976. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Thacker J: The RAD51 gene family, genetic
instability and cancer. Cancer Lett. 219:125–135. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Masson JY, Tarsounas MC, Stasiak AZ,
Stasiak A, Shah R, McIlwraith MJ, Benson FE and West SC:
Identification and purification of two distinct complexes
containing the five RAD51 paralogs. Genes Dev. 15:3296–3307. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Suwaki N, Klare K and Tarsounas M: RAD51
paralogs: Roles in DNA damage signalling, recombinational repair
and tumorigenesis. Semin Cell Dev Biol. 22:898–905. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sinha BK: Topoisomerase inhibitors. A
review of their therapeutic potential in cancer. Drugs. 49:11–19.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pommier Y: Topoisomerase I inhibitors:
Camptothecins and beyond. Nat Rev Cancer. 6:789–802. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Altaha R, Liang X, Yu JJ and Reed E:
Excision repair cross complementing-group 1: Gene expression and
platinum resistance. Int J Mol Med. 14:959–970. 2004.PubMed/NCBI
|
|
23
|
Boulton S, Kyle S and Durkacz BW:
Interactive effects of inhibitors of poly (ADP-ribose. polymerase
and DNA-dependent protein kinase on cellular responses to DNA
damage. Carcinogenesis. 20:199–203. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Haber JE: DNA recombination: The
replication connection. Trends Biochem Sci. 24:271–275. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Arnaudeau C, Lundin C and Helleday T: DNA
double-strand breaks associated with replication forks are
predominantly repaired by homologous recombination involving an
exchange mechanism in mammalian cells. J Mol Biol. 307:1235–1245.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fukutomi T and Akashi-Tanaka S: Prognostic
and predictive factors in the adjuvant treatment of breast cancer.
Breast Cancer. 9:95–99. 2002. View Article : Google Scholar : PubMed/NCBI
|
